The story
Luxembourg’s medical cannabis law took effect on 5 August 2018, giving specially trained doctors a route to prescribe approved cannabis products.[1][2] Patients would obtain treatment through hospital pharmacies, under a programme that began dispensing in February 2019.[3][4]
Patients needed a qualifying illness
The law covered serious, advanced or terminal illness, or illness whose symptoms substantially and persistently harmed quality of life and could be relieved by cannabis.[2] Regulations identified severe chronic pain, chemotherapy-related nausea or vomiting and symptomatic muscle spasticity associated with multiple sclerosis.[3]
Eligibility also depended on a connection to Luxembourg: residence, Luxembourg nationality or coverage by Luxembourg health insurance could qualify a patient.[3] The medical route therefore depended on both clinical criteria and a qualifying personal connection.[3]
Doctors trained before prescribing
Doctors authorised to practise in Luxembourg needed special training before prescribing cannabis.[2] The law required teaching on pharmacology, available forms, indications, adverse effects and the scientific and practical basis for prescribing.[2]
The programme evaluation describes training delivered in January and February 2019, before the first patients entered the pilot.[3] The treatment route brought doctors and hospital pharmacists into the same controlled process for prescribing and dispensing.[3]
Products came through hospital pharmacies
The law’s medical definition included standardised dried flowering tops, extracts, tinctures and oils approved by the health authority.[2] Dispensing was reserved to hospital pharmacies.[2] The evaluation describes a centrally organised programme with a working group and scientific committee overseeing its development.[3]
Patients therefore obtained specified medicinal products through a prescription, with the law assigning responsibility for their quality and supply to the medical system.[3][2] The Luxembourg profile follows that route separately from the later permission to grow cannabis at home.[2]
The programme later changed its flower supply
In November 2024, the Health Ministry announced a reduction in the flower allowance from 100 to 60 grams per twenty-eight days.[4] It also announced the end of replenishment of THC-dominant flower from January 2025, while continuing CBD-dominant and balanced flower.[4]
THC-dominant treatment remained available as oil, alongside balanced and CBD-dominant oils.[4] The ministry cited dosing, administration and adverse-effect concerns in explaining the 2025 changes.[4]
Score by segment 0 to 10
- Possession · 25%2 → 2
- Personal cultivation · 25%1 → 1
- Punishment & enforcement · 20%4 → 4
- Sharing & gifting · 10%1 → 1
- Consumption · 10%2 → 2
- Legal access · 10%0 → 1+1
The bar shows the score after the change; the tick marks where it stood before. Luxembourg's scores have changed again since.
References
- Luxembourg government — Experimental non-medical cannabis access report, 2023Bibliography, law published 1 August 2018 and effective 5 Augustarchived
- Legilux — Drug law, consolidated 21 July 2023Article 30-2archived
- Luxembourg Health Ministry — Medical cannabis programme evaluation, 2022Pages 7–8, medical framework; appendix reproduces 2018 law and regulationsarchived
- Luxembourg Health Ministry — Medical programme changes, 29 November 2024archived
Checked. The date and the event were compared with a source that was read. The score before the change is an editorial estimate.